Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avastin with Docetaxel and Carboplatin in Metastatic NSCLC
NCT00271505Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Dec 2005
- Primary completion
- Jul 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in non-small cell lung cancer (NSCLC), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Time to Progression-Free Survival at 12 months. Started Dec 2005; status: completed.
02
Drugs
bevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00271505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00271505.